Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of March 2006, with the report dated March 22, 2006. The filing serves to disclose a material event regarding U.S. patent litigation rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a legal agreement and does not contain financial statements.
Material Changes
The primary material change disclosed is the announcement of an agreement regarding U.S. clopidogrel patent litigation. This information was originally released via a press release on March 21, 2006, which is incorporated into this filing as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing incorporates a Q&A document (Exhibit 99.2) related to the patent litigation agreement. While the filing highlights the resolution of a specific legal contingency, it does not provide updated financial guidance, general outlook commentary, or a comprehensive risk assessment beyond the context of the litigation settlement.
Investor Verification Checklist
- Review the full text of the March 21, 2006 press release (Exhibit 99.1) for specific terms of the clopidogrel patent litigation agreement.
- Examine the Q&A document (Exhibit 99.2) for management's detailed explanation of the legal settlement's implications.
- Verify the potential financial impact of the litigation agreement on future revenue streams related to clopidogrel in the U.S. market.
- Confirm whether this agreement resolves all outstanding U.S. patent disputes for the product or if other contingencies remain.